DE60210741D1 - Verfahren zur diagnose der alzheimerschen krankheit - Google Patents

Verfahren zur diagnose der alzheimerschen krankheit

Info

Publication number
DE60210741D1
DE60210741D1 DE60210741T DE60210741T DE60210741D1 DE 60210741 D1 DE60210741 D1 DE 60210741D1 DE 60210741 T DE60210741 T DE 60210741T DE 60210741 T DE60210741 T DE 60210741T DE 60210741 D1 DE60210741 D1 DE 60210741D1
Authority
DE
Germany
Prior art keywords
diagnosis
alzheimer
disease
glycoproteins
dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60210741T
Other languages
English (en)
Inventor
Henry Small
Lisa Fodero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monash University
Original Assignee
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monash University filed Critical Monash University
Application granted granted Critical
Publication of DE60210741D1 publication Critical patent/DE60210741D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/415—Assays involving biological materials from specific organisms or of a specific nature from plants
    • G01N2333/42—Lectins, e.g. concanavalin, phytohaemagglutinin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/918—Carboxylic ester hydrolases (3.1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
DE60210741T 2001-01-23 2002-01-23 Verfahren zur diagnose der alzheimerschen krankheit Expired - Lifetime DE60210741D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26384101P 2001-01-23 2001-01-23
PCT/US2002/001874 WO2002059619A2 (en) 2001-01-23 2002-01-23 Method for the diagnosis of alzheimer's disease

Publications (1)

Publication Number Publication Date
DE60210741D1 true DE60210741D1 (de) 2006-05-24

Family

ID=23003453

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60210741T Expired - Lifetime DE60210741D1 (de) 2001-01-23 2002-01-23 Verfahren zur diagnose der alzheimerschen krankheit

Country Status (6)

Country Link
US (1) US20020150878A1 (de)
EP (1) EP1356299B1 (de)
AT (1) ATE323886T1 (de)
CA (1) CA2442708A1 (de)
DE (1) DE60210741D1 (de)
WO (1) WO2002059619A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020033126A (ko) * 2002-03-08 2002-05-04 김용선 병원성 프리온 단백의 n말단의 비효소적 당화반응 최종산물의 검출에 의한 프리온 질환의 진단
GB0508863D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Peptide
CL2007002908A1 (es) 2007-10-09 2008-05-30 Univ Concepcion Procedimiento electroquimico in vitro para evaluar capacidad neurotoxica de estructuras, principios activos y/o compuestos de interes en celulas vivas y que comprende medir y cuantificar los parametros electricos en membranas expuestas a dichos agreg
ES2889914B2 (es) * 2020-07-01 2022-07-21 Univ Miguel Hernandez De Elche PATRON DE GLICOSILACION DE sAPPalfa Y/O sAPPbeta COMO BIOMARCADOR DIAGNOSTICO DE LA ENFERMEDAD DE ALZHEIMER, METODO Y KIT BASADOS EN EL MISMO
WO2022042873A1 (en) 2020-08-27 2022-03-03 Immunologik Gmbh Pharmaceutically acceptable lectins derived from plants, fungi and bacteria for the treatment of sars-cov-2 infections

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1313496C (en) * 1988-04-29 1993-02-09 James Wilson Dennis Diagnostic method to screen tumors
AUPO943297A0 (en) * 1997-09-24 1997-10-16 University Of Melbourne, The Diagnostic test for alzheimer's disease
CA2442733A1 (en) * 2000-04-07 2001-10-18 Axonyx, Inc. Diagnostic test for alzheimer's disease

Also Published As

Publication number Publication date
CA2442708A1 (en) 2002-08-01
ATE323886T1 (de) 2006-05-15
EP1356299A2 (de) 2003-10-29
WO2002059619A3 (en) 2002-10-17
US20020150878A1 (en) 2002-10-17
WO2002059619A2 (en) 2002-08-01
EP1356299B1 (de) 2006-04-19

Similar Documents

Publication Publication Date Title
ATE526041T1 (de) Verfahren zur hemmung okularer vorgänge
CY1112579T1 (el) Μεθοδοι και συνθεσεις για τη διαγνωση του ηλικιακου εκφυλισμου της ωχρας κηλιδας
WO2006134390A3 (en) Method for diagnosing neurodegenerative disease
WO2004044204A3 (fr) Fragments variables d'anticorps de camelides a chaine unique et leurs applications pour le diagnostic et le traitement de pathologies diverses.
DE602004032540D1 (de) Verfahren und vorrichtung zur modelbasierten detektion einer struktur in projektionsdaten
DE60132931D1 (de) Zugriffs- und benutzungsmethoden für webseiten
DE50305049D1 (de) Galactosyl-isomalt, verfahren zu seiner herstellung und verwendung
CA2374521A1 (en) Test question response verification system
ATE399676T1 (de) Verfahren zur herstellung eines sitzsystems
SG126114A1 (en) Method and system for improving quality in a service industry
DE602004019812D1 (de) Marker für neuromyelitis optica
DE50208978D1 (de) Verfahren zur Herstellung eines Gehäuses für Sensorelemente, sowie Sensor, und dessen Verwendung
AU2003217652A8 (en) Methods for continuous performance testing
WO2008034016A3 (en) Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins
ATE391954T1 (de) Verfahren zur steuerung eines ressourcenzugriffs eines prozesses durch einen elternprozess
PT1560812E (pt) Compostos de aminociclohexil eter e suas utilizacoes
HK1093757A1 (en) Diagnostic for osteoporosis
DE10081270D2 (de) Verfahren zur prozessgesteuerten und kundenindividuellen Herstellung eines Gegenstandes
ATE452655T1 (de) Verwendung von l-polynukleotiden zur diagnostischen bilderzeugung
WO2001058476A3 (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
WO2002068679A3 (de) Ermittlung des patientenbezogenen kariesrisikos
DE60210741D1 (de) Verfahren zur diagnose der alzheimerschen krankheit
WO2004107958A3 (en) Sterol markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
ATE422334T1 (de) System und verfahren zur gewebeanalyse
AU2002238766A1 (en) Diagnostic screens for alzheimer's disease

Legal Events

Date Code Title Description
8332 No legal effect for de